PRESS RELEASE

Saclay, 30 May 2013

The CEA and ELEKTA sign
a partnership agreement in the field of radiotherapy

The CEA-List Institute has signed a research partnership in the field of radiotherapy with ELEKTRA, a global supplier of cancer treatment systems. This collaboration falls within the scope of the new DOSEO1 platform, with its technology dedicated to radiotherapy and imaging.

R&D activities conducted using the DOSEO platform are located at the CEA Saclay site and are geared towards fulfilling four key tasks: developing innovative technologies in radiotherapy and imaging, controlling these new systems (metrology, quality control) for safer, higher performance treatments, bringing together different stakeholders in the field and providing training on the developed innovations for personnel and students.

The first collaborative research completed by ELEKTA and the CEA-List Institute focus on developing software dedicated to full dosimetric characterization of radiotherapy equipment designed by ELEKTA (accelerators, multileaf collimators2, EPID image devices3). CEA-List will also provide expertise in the field of metrology and quality control, via the LNHB4. The agreement will also cover training for medical personnel and students, as well as ELEKTA customers, using the experimental resources available within the DOSEO platform.

For François Pointurier, CEO of ELEKTA SAS, “ELEKTA has fostered a culture of innovation that is built through close collaboration with our customers and partners; consequently, this partnership is a logical and robust agreement, which I am convinced will develop the innovations of tomorrow and provide support for their use through training."

For Karine Gosse, Director of the CEA-List Institute, “In addition to the transfer of innovative technologies from our Institute, this agreement is also representative of our strong involvement in the field of digital technology for the health sector, particularly radiotherapy."

This collaborative research is set in a national context where different monitoring actions are implemented by the Institut national du Cancer (French national cancer institute, INCa) to guarantee the safety of patients, improve the quality of radiotherapy treatment and provide support to develop practices in this field.

---

1 The DOSEO Platform is coordinated by the French National Cancer Institute (INCa), the French National Metrology and Testing Laboratory (LNE) and the French National Institute for Nuclear Science and Technology (INSTN) and supported by the Paris-Saclay super campus, the Essonne General Council, the Ile-de-France region, the European Regional Development Fund (ERDF), the Directorate General for Competitiveness, Industry and Services (DGIS) and the Medicine competitiveness cluster.

2 Devices designed to shape particle beams spatially, thus irradiating the area to be treated more accurately.

3 Electronic Portal Imaging Device: electronic system designed to produce control images in radiotherapy to measure the dose delivered to the patient.

4 The Laboratoire national Henri Becquerel is the national metrology laboratory in the field of ionising radiation.
About CEA-List

The French Atomic Energy and Alternative Energies Commission (CEA) is a public sector research body active in four main fields: carbon-based energy, information and healthcare technologies, very large-scale research infrastructures (TGIR), and defence and global security. Drawing on excellence in fundamental research and widely-recognized expertise capabilities, the CEA is involved in setting up collaborative projects with many academic and industrial partners. With 16,000 researchers and other employees, the CEA is a major player in the European research community with a growing international presence.

Within the department of technological research, completing CEA Tech activities, the CEA-List Institute focuses its research on smart digital systems. Major economic and social drivers, its R&D programmes are focused on advanced manufacturing (robotics and virtual reality, non-destructive testing, vision), embedded systems (architectures, software and systems engineering), and ambient intelligence (sensors, instrumentation, and data processing). By developing cutting-edge technological research, CEA LIST helps its industrial partners enhance their competitiveness through innovation and technology transfer (www-list.cea.fr).

About ELEKTA

ELEKTA is a medical technology company, a pioneer with important innovations and clinical solutions for the treatment of cancer and brain disorders. It develops highly sophisticated tools and treatment planning systems, used in radiotherapy, radiosurgery and brachytherapy, as well as procedure optimization software that covers all therapeutic solutions for cancer. Exceeding the limits of science and technology by proposing smart and cost-efficient solutions in which health professionals and patients can have full confidence, ELEKTA’s objective is to improve, extend and even save human lives.

Today, ELEKTA solutions in the fields of oncology and neurosurgery are used in more than 6,000 hospitals across the globe. ELEKTA employs around 3 400 people worldwide. The head office is located in Stockholm, in Sweden, and the company is listed on the Nordic Stock Exchange under the ticker symbol EKTab. Website: www.elekta.com.

Press contacts:

ELEKTA: Marie-Madeleine Legrais - Marie.M.Legrais@elekta.com - +33 1 55 95 83 53

CEA: Coline Verneau - coline.verneau@cea.fr - +33 1 64 50 14 88